Skip to main
PRCT
PRCT logo

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics Corp has demonstrated a consistent average growth of approximately 6.1% per quarter in handpiece utilization over the past six quarters, indicating a robust increase in the adoption of its surgical systems. In early 2024, the company strategically focused on curtailing operating expenses to grow at half the pace of top-line growth, signaling a commitment to achieving profitability amidst market challenges. Additionally, management expressed confidence in the strong visibility of its pipeline and reported 58 new system placements in the most recent quarter, surpassing their previous guidance and suggesting a positive trajectory for future revenue growth.

Bears say

PROCEPT BioRobotics has experienced a significant decline in its stock price, down approximately 54% year-to-date, indicating a challenging financial landscape despite the company's ability to exceed its own guidance. Key factors contributing to a negative outlook include potential declines in capital equipment demand, reduced usage of handpieces by customers, and increased competitive pressures, alongside concerns regarding changes in reimbursement for its Aquablation therapy. The anticipated consensus for future sales in 2026 may also see downward adjustments as investors react to these ongoing concerns regarding utilization and inventory levels.

PRCT has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 7 analysts, PRCT has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.